Boston Scientific Corporation $BSX Shares Purchased by Panagora Asset Management Inc.

Key Points

• Panagora Asset Management Inc. increased its stake in Boston Scientific Corporation by 17.8%, acquiring an additional 167,844 shares, bringing its total ownership to over 1.1 million shares valued at approximately $112.1 million.
• Insider selling activity was observed as two executives sold a combined total of 67,313 shares, reducing their positions by over 21% and 42%, respectively.
• Boston Scientific reported better-than-expected quarterly earnings with earnings per share of $0.75, exceeding analysts' estimates and indicating a year-over-year revenue increase of 22.8% to $5.06 billion.

Panagora Asset Management Inc. lifted its position in Boston Scientific Corporation (NYSE:BSX - Free Report) by 17.8% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,111,377 shares of the medical equipment provider's stock after buying an additional 167,844 shares during the period. Panagora Asset Management Inc. owned approximately 0.08% of Boston Scientific worth $112,116,000 as of its most recent SEC filing.

Several other large investors also recently bought and sold shares of BSX. Brighton Jones LLC grew its position in Boston Scientific by 0.8% during the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock worth $2,445,000 after purchasing an additional 226 shares during the last quarter. Bank Pictet & Cie Europe AG grew its position in Boston Scientific by 40.8% during the 4th quarter. Bank Pictet & Cie Europe AG now owns 73,096 shares of the medical equipment provider's stock worth $6,529,000 after purchasing an additional 21,173 shares during the last quarter. Highview Capital Management LLC DE grew its position in Boston Scientific by 6.2% during the 4th quarter. Highview Capital Management LLC DE now owns 24,507 shares of the medical equipment provider's stock worth $2,189,000 after purchasing an additional 1,439 shares during the last quarter. Rehmann Capital Advisory Group grew its position in Boston Scientific by 6.9% during the 4th quarter. Rehmann Capital Advisory Group now owns 5,245 shares of the medical equipment provider's stock worth $468,000 after purchasing an additional 339 shares during the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in shares of Boston Scientific in the 4th quarter valued at $26,702,000. Hedge funds and other institutional investors own 89.07% of the company's stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Arthur C. Butcher sold 17,313 shares of the firm's stock in a transaction dated Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the transaction, the executive vice president directly owned 23,600 shares of the company's stock, valued at approximately $2,469,268. This trade represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Edward J. Ludwig sold 4,000 shares of the firm's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $106.03, for a total transaction of $424,120.00. Following the sale, the director owned 18,479 shares of the company's stock, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders sold 174,214 shares of company stock valued at $18,397,457. Corporate insiders own 0.50% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the stock. UBS Group upped their price objective on shares of Boston Scientific from $130.00 to $135.00 and gave the company a "buy" rating in a report on Thursday, July 24th. Erste Group Bank raised shares of Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Barclays upped their price objective on shares of Boston Scientific from $125.00 to $133.00 and gave the company an "overweight" rating in a report on Thursday, July 24th. Royal Bank Of Canada reaffirmed an "outperform" rating on shares of Boston Scientific in a report on Thursday, July 24th. Finally, Jefferies Financial Group reaffirmed a "hold" rating on shares of Boston Scientific in a report on Monday, July 21st. Three analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $117.50.

Boston Scientific Price Performance

Shares of NYSE:BSX traded up $0.55 during midday trading on Thursday, hitting $108.08. The company's stock had a trading volume of 3,069,887 shares, compared to its average volume of 7,457,655. The business's 50 day simple moving average is $104.71 and its 200 day simple moving average is $102.18. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The company has a market cap of $160.15 billion, a P/E ratio of 64.33, a price-to-earnings-growth ratio of 2.54 and a beta of 0.65. Boston Scientific Corporation has a 12-month low of $80.50 and a 12-month high of $108.94.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. The firm had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. The company's revenue for the quarter was up 22.8% on a year-over-year basis. During the same period last year, the firm posted $0.62 earnings per share. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. On average, analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current year.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.